Clinical Trials in Bay Pines, Florida
17 recruiting
Showing 1–17 of 17 trials
Recruiting
Phase 3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca990 enrolled266 locationsNCT06878261
Recruiting
Not Applicable
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Adenocarcinoma of the RectumAdenocarcinoma of the Colon
NRG Oncology9,500 enrolled478 locationsNCT05080673
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
AstraZeneca830 enrolled288 locationsNCT06868277
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AstraZeneca880 enrolled300 locationsNCT06692738
Recruiting
Not Applicable
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Lung Neoplasm
VA Office of Research and Development670 enrolled17 locationsNCT02984761
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Non-squamous Non-small Cell Lung Cancer
AstraZeneca878 enrolled282 locationsNCT06627647
Recruiting
Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Stage III Prostate Cancer AJCC v8Prostate AdenocarcinomaStage IVA Prostate Cancer AJCC v8
NRG Oncology1,209 enrolled383 locationsNCT05946213
Recruiting
Phase 2
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
Non Muscle Invasive Bladder Cancer
White River Junction Veterans Affairs Medical Center240 enrolled8 locationsNCT05796375
Recruiting
Phase 3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Locally Advanced Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8
NRG Oncology474 enrolled466 locationsNCT05624996
Recruiting
Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
Prostate Adenocarcinoma
NRG Oncology2,050 enrolled575 locationsNCT05050084
Recruiting
Phase 3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Daiichi Sankyo686 enrolled100 locationsNCT06899126
Recruiting
Phase 3
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC663 enrolled81 locationsNCT07164443
Recruiting
Phase 2Phase 3
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Prostate CancerMetastatic Prostate CancerOligometastasis+3 more
VA Office of Research and Development464 enrolled20 locationsNCT04787744
Recruiting
Phase 2
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Metastatic Castrate Resistant Prostate CancerBARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2RAD51B, RAD51C, RAD51D, or RAD54L Mutations
VA Office of Research and Development100 enrolled18 locationsNCT04038502
Recruiting
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
Lung CancerPulmonary Nodule, Solitary
Veracyte, Inc.2,400 enrolled23 locationsNCT06426628